Forward Citations = 4

Loading Chart...

3 inventors (with patents filed for the assignee):

Ashish Nimgaonkar (5 out of 9 patents)

Steven C Polomoscanik (5 out of 5 patents)

Thomas Henry Jozefiak (5 out of 20 patents)

5 patents: Sort by Forward Citations

1. 12059432 - Substituted phenyl boronic acid containing polymers and methods of use (2024-08-13),

2. 11576928 - Substituted phenyl boronic acid containing polymers and methods of use (2023-02-14),

3. 11491183 - Substituted phenyl boronic acid containing polymers and methods of use (2022-11-08),

4. 11491182 - Substituted phenyl boronic acid containing polymers and methods of use (2022-11-08),

5. 11484548 - Substituted phenyl boronic acid containing polymers and methods of use (2022-11-01),

Glyscend, Inc. is a biotechnology company focused on the development of novel therapies for metabolic diseases. The company's flagship product is an innovative oral therapy for diabetes, designed to improve glycaemic control without the need for injections. Glyscend is dedicated to revolutionizing the way diabetes is managed, offering patients a more convenient and effective treatment option.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

5 Patents

#102 in Baltimore, MD

#749 in Maryland

#51,545 in US

Baltimore, MD, United States of America

Glyscend, Inc.

Forward Citations = 4

3 inventors:

Ashish Nimgaonkar (5 out of 9 patents)

Steven C Polomoscanik (5 out of 5 patents)

Thomas Henry Jozefiak (5 out of 20 patents)

Please report any incorrect information to [email protected]